Aspirin resistance
GJ Hankey, JW Eikelboom - The Lancet, 2006 - thelancet.com
Aspirin resistance is the inability of aspirin to reduce platelet production of thromboxane A 2
and thereby platelet activation and aggregation. Increasing degrees of aspirin resistance …
and thereby platelet activation and aggregation. Increasing degrees of aspirin resistance …
Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement
W Hochholzer, D Trenk, HP Bestehorn… - Journal of the American …, 2006 - jacc.org
Objectives: Our prospective study tested the hypothesis that the 30-day clinical outcome of
elective percutaneous catheter intervention (PCI) differs between strata defined by quartiles …
elective percutaneous catheter intervention (PCI) differs between strata defined by quartiles …
Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance
EI Lev, RT Patel, KJ Maresh, S Guthikonda… - Journal of the American …, 2006 - jacc.org
Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary
Intervention: The Role of Dual Drug Resistance Eli I. Lev, Rajnikant T. Patel, Kelly J. Maresh …
Intervention: The Role of Dual Drug Resistance Eli I. Lev, Rajnikant T. Patel, Kelly J. Maresh …
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic …
BACKGROUND: Dual antiplatelet therapy with aspirin and clopidogrel is standard for
prevention of thrombotic complications of percutaneous coronary intervention (PCI) …
prevention of thrombotic complications of percutaneous coronary intervention (PCI) …
[HTML][HTML] High post‐treatment platelet reactivity identified low‐responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting …
Background and objectives: Low response to antiplatelet therapy may be a risk factor for the
development of ischemic complications in patients with non‐ST segment elevation acute …
development of ischemic complications in patients with non‐ST segment elevation acute …
Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non–ST-segment elevation acute coronary syndrome …
Objectives: We analyzed the benefit of a 600-mg clopidogrel loading dose on platelet
reactivity and clinical outcomes after stenting for non–ST-segment elevation acute coronary …
reactivity and clinical outcomes after stenting for non–ST-segment elevation acute coronary …
Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel
DJ Angiolillo, A Fernandez-Ortiz… - … , and vascular biology, 2006 - Am Heart Assoc
Objectives—Metabolic activity of cytochrome P450 (CYP) 3A4 has been associated with
clopidogrel response variability. Because metabolic activity of CYP3A4 is genetically …
clopidogrel response variability. Because metabolic activity of CYP3A4 is genetically …
Drug insight: clopidogrel nonresponsiveness
Platelet reactivity to agonists and subsequent activation are important factors that affect the
development of atherothrombosis and resultant ischemic events. Pharmacologic …
development of atherothrombosis and resultant ischemic events. Pharmacologic …
Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers
MJ Price, JL Coleman, SR Steinhubl, GB Wong… - The American journal of …, 2006 - Elsevier
An increased loading dose of clopidogrel has been shown to provide more intense and
rapid platelet inhibition (PI) than the standard 300-mg dose. However, patient variability in PI …
rapid platelet inhibition (PI) than the standard 300-mg dose. However, patient variability in PI …
Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A single ascending dose study in healthy humans
F Asai, JA Jakubowski, H Naganuma, JT Brandt… - Platelets, 2006 - Taylor & Francis
We assessed the tolerability, pharmacodynamics as measured by inhibition of platelet
aggregation (IPA), and pharmacokinetics of prasugrel (CS-747, LY640315), a novel …
aggregation (IPA), and pharmacokinetics of prasugrel (CS-747, LY640315), a novel …